Maze Therapeutics (MAZE) Income towards Parent Company (2024 - 2026)

Maze Therapeutics has disclosed Income towards Parent Company across 3 years of filings, most recently posting -$24.2 million for Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$24.2 million, up 26.16% year-over-year; the trailing twelve-month figure through Mar 2026 was -$122.5 million (down 336.18% YoY), and the FY2025 annual result was -$131.1 million, down 351.17% from the prior year.
• Income towards Parent Company came in at -$24.2 million for Q1 2026 at Maze Therapeutics, up from -$34.6 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $139.1 million in Q2 2024 to a low of -$34.6 million in Q4 2025.
• The 3-year median for Income towards Parent Company is -$29.7 million (2024), against an average of -$10.9 million.
• Across the five-year window, Income towards Parent Company slumped 124.22% in 2025 and rose 26.16% in 2026, its largest moves.
• Maze Therapeutics' Income towards Parent Company stood at -$29.7 million in 2024, then retreated by 16.57% to -$34.6 million in 2025, then increased by 29.97% to -$24.2 million in 2026.
• The last three Income towards Parent Company figures came in at -$24.2 million (Q1 2026), -$34.6 million (Q4 2025), and -$30.1 million (Q3 2025), per Business Quant data.